Annexin A protein family in atherosclerosis

Yong-Zhen Li1, Yan-Yue Wang1, Liang Huang2

  • 1Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, People's Republic of China.

Insights

Annexin A (AnxA) proteins are key drivers of atherosclerosis development. Targeting AnxA family members may offer a novel strategy to prevent cardiovascular ischemic events.

Area of Science:

  • Vascular Biology
  • Molecular Medicine
  • Immunology

Background:

  • Atherosclerosis is a chronic vascular pathology causing most cardiovascular ischemic events.
  • It involves endothelial dysfunction, inflammation, lipid accumulation, and cell death.
  • Annexin A (AnxA) proteins regulate inflammation and cell signaling.

Purpose of the Study:

  • To discuss the roles of AnxA1, AnxA2, AnxA5, and AnxA7 in atherosclerosis.
  • To explore the mechanisms underlying AnxA involvement in atherogenesis.
  • To propose AnxA proteins as therapeutic targets for atherosclerosis.

Main Methods:

  • Literature review of AnxA family proteins in atherosclerosis.
  • Analysis of AnxA functions in cellular processes relevant to atherosclerosis.
  • Synthesis of evidence on AnxA involvement in atherogenesis.

Main Results:

  • AnxA1, AnxA2, AnxA5, and AnxA7 play significant roles in atherosclerosis development.
  • These AnxA proteins are involved in inflammation, cell signaling, and cell fate.
  • Evidence suggests AnxAs actively drive atherosclerosis progression.

Conclusions:

  • AnxA proteins are identified as critical drivers of atherosclerosis.
  • Targeting AnxA expression or function presents a potential therapeutic avenue.
  • Intervention against AnxA family may prevent atherosclerosis progression and cardiovascular events.

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
112
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
52
Inflammation01:38

Inflammation

Overview
55.6K
Aneurysm I: Introduction01:30

Aneurysm I: Introduction

An aortic aneurysm is a localized outpouching or dilation at a weak point in the artery wall. It may involve different parts of the aorta, such as the abdominal aorta, aortic arch, or thoracic aorta.Etiological factorsSeveral disorders are associated with aortic aneurysms.Congenital causes, such as primary connective tissue disorders like Marfan syndrome, impact the integrity and strength of connective tissues, notably affecting the aorta. Marfan syndrome is a genetic disorder that specifically...
34
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.1K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
50